Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab adizutecan plus FOLFOX versus standard of care for first-line metastatic pancreatic ductal adenocarcinoma
2025-522563-15-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing Telisotuzumab adizutecan + FOLFOX with Standard of care chemotherapy (2 arms). Primary endpoints: Objective response and Overall survival. Planned start Jul 2026; status: authorised.
02
Drugs
telisotuzumab adizutecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2025-522563-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522563-15-00.